SEARCH:   Advanced

Blood, 1 November 2005, Vol. 106, No. 9, pp. 2969-2976. Prepublished online as a Blood First Edition Paper on July 5, 2005; DOI 10.1182/blood-2004-09-3544. This Article Full Text (PDF) All Versions of this Article: 2004-09-3544v1 106/9/2969    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Crawley, C. Articles by Apperley, J. F Search for Related Content PubMed PubMed Citation Articles by Crawley, C. Articles by Apperley, J. F Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 13, 2004 Accepted June 2, 2005 Outcomes of reduced intensity transplantation for chronic myeloid leukaemia: an analysis of prognostic factors from the chronic leukemia working party of the EBMT Charles Crawley*, Richard Szydlo, Marc Lalancette, Andrea Bacigalupo, Andrzej Lange, Mats Brune, Gunnar Juliusson, Arnon Nagler, Alois Gratwohl, Jacob Passweg, Mieczyslaw Komarnicki, Antonin Vitek, Jiri Mayer, Axel Zander, Jorge Sierra, Alesssandro Rambaldi, Olle Ringden, Dietger Niederwieser, and Jane F Apperley Addenbrooke's Hospital, Cambridge, United Kingdom Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom CHUQ L'Hotel-Dieu, Quebec, Canada Ospedale San Martino, Genova, Italy Lower Silesian Centre for Cellular Transplantation, Wroclaw, Poland Sahlgrenska University Hospital, Goeteborg, Sweden University Hospital, Lund, Sweden Chaim Sheba Medical Center, Tel-Hashomer, Israel University Hospital, Basel, Switzerland University of Medical Science, Poznan, Poland Institute of Hematology and Blood Transfusion, Prague, Czech Republic University Hospital, Brno, Czech Republic University Hospital Eppendorf, Hamburg, Germany Hospital Santa Creu I Sant Pau, Barcelona, Spain Ospedale Bergamo, Bergamo, Italy Huddinge University Hospital, Huddinge, Sweden University of Leipzig, Leipzig, Germany * Corresponding author; email: charles.crawley{at}addenbrookes.nhs.uk. This study reports outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning (RIC) in 186 patients with chronic myeloid leukaemia (CML) from the European Blood and Marrow Transplantation group. The median age was 50, 64% were in 1st chronic phase (CP), CP2 13%, accelerated phase 17% and blast crises 6%. The median EBMT transplant score was 3. The day 100 transplantation related mortality (TRM) was 6.1% (CI: 3.4-11) but rose to 23.3% (CI: 14-27) at 2 years. Fludarabine, busulfan and anti-thymocyte globulin (Fd/Bu/ATG) was associated with the lowest TRM of 11.6% (CI: 4.7-11) at 1 year. Acute graft versus host disease (GvHD) grade II-IV occurred in 32% and chronic GvHD in 43% (extensive in 24%). ATG was associated with a lower incidence of cGvHD. The overall (OS) and progression free survivals (PFS) at 3 years were 58% (CI: 50-66) and 37% (CI: 30-45) respectively. Adverse OS was associated with advanced disease (RR 3.4). PFS was inferior in advanced disease (RR 2.7) and a trend to improved outcomes with Fd/Bu/ATG (RR 0.58). RIC allografts are feasible in CML in 1st or 2nd CP. Since no other RIC regimen demonstrated superiority Fd/Bu/ATG should be considered as baseline in future prospective trials. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Ayuk, J. A. Perez-Simon, A. Shimoni, A. Sureda, T. Zabelina, R. Schwerdtfeger, R. Martino, H. G. Sayer, A. Alegre, J.-J. Lahuerta, et al. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation Haematologica, September 1, 2008; 93(9): 1343 - 1350. [Abstract] [Full Text] [PDF] N. B. Heaney, M. Copland, K. Stewart, J. Godden, A. N. Parker, I. G. McQuaker, G. M. Smith, C. Crawley, P. Shepherd, and T. L. Holyoake Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia Blood, May 15, 2008; 111(10): 5252 - 5255. [Abstract] [Full Text] [PDF] E. Olavarria, S. Siddique, M. J. Griffiths, S. Avery, J. L. Byrne, K. P. Piper, A. L. Lennard, L. Pallan, J. M. Arrazi, J. B. Perz, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia Blood, December 15, 2007; 110(13): 4614 - 4617. [Abstract] [Full Text] [PDF] P. Kebriaei, M. A. Detry, S. Giralt, A. Carrasco-Yalan, A. Anagnostopoulos, D. Couriel, I. F. Khouri, P. Anderlini, C. Hosing, A. Alousi, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia Blood, November 1, 2007; 110(9): 3456 - 3462. [Abstract] [Full Text] [PDF] J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] D. A. Rizzieri, L. P. Koh, G. D. Long, C. Gasparetto, K. M. Sullivan, M. Horwitz, J. Chute, C. Smith, J. Z. Gong, A. Lagoo, et al. Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution J. Clin. Oncol., February 20, 2007; 25(6): 690 - 697. [Abstract] [Full Text] [PDF] J. H. Antin Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2 Hematology, January 1, 2007; 2007(1): 47 - 54. [Abstract] [Full Text] [PDF] M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, September 15, 2006; 108(6): 1809 - 1820. [Abstract] [Full Text] [PDF] A. Quintas-Cardama and J. E. Cortes Chronic Myeloid Leukemia: Diagnosis and Treatment Mayo Clin. Proc., July 1, 2006; 81(7): 973 - 988. [Abstract] [Full Text] [PDF] M. J. Mauro and R. T. Maziarz Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used? Mayo Clin. Proc., March 1, 2006; 81(3): 404 - 416. [Abstract] [Full Text] [PDF] J. F. Apperley Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation Hematology, January 1, 2006; 2006(1): 226 - 232. [Abstract] [Full Text] [PDF] B. L. Scott and B. M. Sandmaier Outcomes with Myeloid Malignancies Hematology, January 1, 2006; 2006(1): 381 - 389. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020